Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis
| Autor: | Somnath Sarkar, Tu Duong, N. H. Bjarnason, Pierre D. Delmas, Bruce H. Mitlak, C. Christiansen |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Bone disease Endocrinology Diabetes and Metabolism Osteocalcin Osteoporosis Urology Enzyme-Linked Immunosorbent Assay Bone remodeling Risk Factors medicine Humans Raloxifene Risk factor Osteoporosis Postmenopausal Chi-Square Distribution biology business.industry Estrogen Antagonists Odds ratio Alkaline Phosphatase medicine.disease Surgery Vertebra Logistic Models medicine.anatomical_structure Raloxifene Hydrochloride Multivariate Analysis biology.protein Spinal Fractures Female Bone Remodeling Collagen business Biomarkers medicine.drug |
| Zdroj: | Osteoporosis International. 12:922-930 |
| ISSN: | 1433-2965 0937-941X |
| DOI: | 10.1007/s001980170020 |
| Popis: | We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnover was significantly related to future risk of vertebral fracture, also after adjusting for baseline vertebral fracture status and BMD. Thus, for a decrease of 9.3 pg/l in serum osteocalcin after 1 year's raloxifene therapy, the odds ratio (OR) for a new vertebral fracture during 3 years was 0.69 (0.54-0.88), p = 0.003. Similarly, for a decrease of 5.91 microg/l in serum bone alkaline phosphatase, OR was 0.75 (0.62-0.92), p = 0.005. The change in BMD over 12 and 24 months was not related to fracture risk in any of the analyses. The strongest predictor for vertebral fracture was prevalent vertebral fracture--even during therapy. The predictive value of baseline BMD was in the same order of magnitude as bone turnover change during raloxifene treatment. In conclusion, the change in bone turnover is related to fracture risk during raloxifene therapy. In contrast the change in BMD is not related to fracture risk. The strongest predictor for vertebral fracture is prevalent vertebral fracture. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink